Post-earnings recap
Reported
Mon, Aug 6, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arcus Biosciences reported a loss of $0.32 per share, which did not meet any consensus expectations as revenue figures were not disclosed. The stock reacted negatively, dropping 1.09%, likely due to the lack of guidance and clarity on future performance. Investors may be cautious as the company continues to focus on its clinical programs without specific financial targets.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.32 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges ahead but emphasized their commitment to ongoing research and development. They did not provide any specific guidance for future performance.
Management did not provide specific financial guidance for the upcoming quarters.
The company is focused on advancing its clinical programs.